Charles River Laboratories International Inc
NYSE:CRL
Intrinsic Value
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies... [ Read More ]
The intrinsic value of one CRL stock under the Base Case scenario is 268.97 USD. Compared to the current market price of 270.95 USD, Charles River Laboratories International Inc is Overvalued by 1%.
Valuation Backtest
Charles River Laboratories International Inc
Run backtest to discover the historical profit from buying and selling CRL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Charles River Labs: Stable 2023, Modest 2024 Growth
2023-Q4 Earnings Call
In 2023, Charles River Laboratories showcased its resilient business model, achieving a 6.5% organic revenue growth and an earnings per share (EPS) of $10.67, aligning with the higher end of its forecasts. Despite a broader life sciences downturn, the company generated $4.13 billion in revenue, driven by its Safety Assessment business and growth in the RMS segment. However, operating margins dipped by 130 basis points to 19.1% in Q4, influenced by higher costs and lower Discovery sales, contributing to a 4% annual EPS decline to $10.67. Looking at 2024, constrained spending may persist, yet the firm anticipates stabilization and a flat to 3% organic revenue growth. Non-GAAP EPS projection is $10.90 to $11.40, factoring in a minimum 50 basis-point operating margin expansion.
Balance Sheet Decomposition
Charles River Laboratories International Inc
Current Assets | 1.6B |
Cash & Short-Term Investments | 276.8m |
Receivables | 780.4m |
Other Current Assets | 551.4m |
Non-Current Assets | 6.6B |
Long-Term Investments | 243.8m |
PP&E | 2B |
Intangibles | 4B |
Other Non-Current Assets | 349.7m |
Current Liabilities | 1.1B |
Accounts Payable | 168.9m |
Accrued Liabilities | 496m |
Other Current Liabilities | 390.1m |
Non-Current Liabilities | 3.5B |
Long-Term Debt | 2.6B |
Other Non-Current Liabilities | 895.9m |
Earnings Waterfall
Charles River Laboratories International Inc
Revenue
|
4.1B
USD
|
Cost of Revenue
|
-2.6B
USD
|
Gross Profit
|
1.5B
USD
|
Operating Expenses
|
-869.9m
USD
|
Operating Income
|
659.3m
USD
|
Other Expenses
|
-184.7m
USD
|
Net Income
|
474.6m
USD
|
Free Cash Flow Analysis
Charles River Laboratories International Inc
What is Free Cash Flow?
CRL Profitability Score
Profitability Due Diligence
Charles River Laboratories International Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Charles River Laboratories International Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
CRL Solvency Score
Solvency Due Diligence
Charles River Laboratories International Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Charles River Laboratories International Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRL Price Targets Summary
Charles River Laboratories International Inc
According to Wall Street analysts, the average 1-year price target for CRL is 269.35 USD with a low forecast of 237.35 USD and a high forecast of 304.5 USD.
Ownership
CRL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRL Price
Charles River Laboratories International Inc
Average Annual Return | 18.39% |
Standard Deviation of Annual Returns | 45.32% |
Max Drawdown | -64% |
Market Capitalization | 13.9B USD |
Shares Outstanding | 51 349 800 |
Percentage of Shares Shorted | 3.9% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The firm provides research models required in research and development of new drugs, devices, and therapies. The firm's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions (Biologics), and Avian Vaccine Services (Avian).
Contact
IPO
Employees
Officers
The intrinsic value of one CRL stock under the Base Case scenario is 268.97 USD.
Compared to the current market price of 270.95 USD, Charles River Laboratories International Inc is Overvalued by 1%.